🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in France / NCT04328298
Recruiting Observational

French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)

NCT04328298 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2019-12-19
Last updated
2026-03-04

Condition(s) studied

Hematopathology Eligible or CAR-t Cell Treatment

Study summary

This study is a registry including prospective and retrospective data on all patients who have been presented in a Multidisciplinary tumor board or RCP to be eligible for CAR-T cell treatment.

Eligibility

Sex
ALL
Min age
0 Years
Max age
99 Years
Healthy volunteers
No
Inclusion Criteria: Retrospective inclusion : * Patient treated with CAR-T from 1 July 2018 under temporary authorization (ATU) or covered by French health insurance system (under post-ATU or MA) in a qualified center before activation of this register in this center * If the patient is alive, the patient has been informed of the collection and use of their data, and the patient has not opposed this use. If the patient has died, the patient did not opposed the use of their data while alive Prospective inclusion : * Patient eligible for a treatment with CAR-T for an hematological malignancy which is covered by French health insurance (for ATUs / post-ATUs or MA), or as part of a clinical trial with the same indication, after the activation of this register in this center. * Patient whose CAR-T indication has been validated during a multidisciplinary tumor board (RCP) of a qualified center, according to the ministerial order of 8 August 2019 * Patient deemed eligible for a treatment with CAR-T after a medical exam performed in a qualified center according to the ministerial order of 8 August 2019 * If the patient is alive, the patient has been informed of the collection and use of their data, and the patient has not opposed this use. If the patient has died, the patient did not opposed the use of their data while alive. Exclusion Criteria Patient not registered with the social security in France

Primary outcome measure(s)

Trial sites (36)

FacilityCityRegionStatus
CHU d'Amiens - Hôpital Sud Amiens France Recruiting
CHU Angers Angers France Recruiting
CHRU Besançon - Hôpital Minjoz Besançon France Recruiting
CHU de Brest - Hôpital du Morvan Brest France Recruiting
Institut d'Hématologie de Basse Normandie Caen France Recruiting
CHU d'Estaing Clermont-Ferrand France Recruiting
APHP - Hôpital Henri Mondor Créteil France Recruiting
CHU de Dijon Dijon France Recruiting
CHU de Grenoble La Tronche France Recruiting
CHRU de Lille - Hôpital Claude Hurriez Lille France Recruiting
Hôpital Dupuytren Limoges France Recruiting
Centre Léon Bérard Lyon France Recruiting
Institut d'Hématologie et d'Oncologie Pédiatrique (IHOP) Lyon France Recruiting
Hôpital de la Timone Marseille France Recruiting
Institut Paoli Calmette Marseille France Recruiting
CHU de Montpellier Montpellier France Recruiting
CHU de Nantes - Hôtel Dieu Nantes France Recruiting
CHU de Nice Nice France Recruiting
APHP - Hôpital Cochin Paris France Recruiting
APHP - Hôpital La Pitié Salpêtrière Paris France Recruiting
APHP - Hôpital Necker Paris France Recruiting
APHP - Hôpital Saint Antoine Paris France Recruiting
APHP - Hôpital Saint Louis Paris France Recruiting
APHP - Hôpital Universitaire Robert Debré Paris France Recruiting
Centre Francois Magendie Pessac France Recruiting
Centre Hospitalier Lyon Sud Pierre-Bénite France Recruiting
Hôpital de la Milétrie - CHU de Poitiers Poitiers France Recruiting
CHU de Rennes - Hôpital Pontchaillou Rennes France Recruiting
Centre Henri Becquerel Rouen France Recruiting
CHU de Rouen Normandie Rouen France Recruiting
Institut de Cancérologie Hématologie Universitaire de Saint Etienne Saint-Priest-en-Jarez France Recruiting
ICANS (Institut de Cancérologie Strasbourg Europe) Strasbourg France Recruiting
Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O) Toulouse France Recruiting
CHU Bretonneau Tours France Recruiting
CHU Brabois Vandœuvre-lès-Nancy France Recruiting
Gustave Roussy Cancer Campus Villejuif France Recruiting

More The Lymphoma Academic Research Organisation trials in France

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04328298 on ClinicalTrials.gov ↗ ← All trials in France